SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

11 Aug 2022 Evaluate
The sales is pegged at Rs. 1652.76 millions for the June 2022 quarter. The mentioned figure indicates a decline of about -34.09% as against Rs. 2507.58 millions during the year-ago period.The Net Profit of the company slipped to Rs. 210.52 millions from Rs. 312.07 millions, a decline of -32.54% on QoQ basis.Operating Profit reported a sharp decline to 335.54 millions from 468.76 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1652.76 2507.58 -34.09 1652.76 2507.58 -34.09 7791.56 4876.99 59.76
Other Income 3.75 12.28 -69.46 3.75 12.28 -69.46 31.04 37.33 -16.85
PBIDT 335.54 468.76 -28.42 335.54 468.76 -28.42 1488.20 876.53 69.78
Interest 9.08 12.09 -24.90 9.08 12.09 -24.90 48.47 136.33 -64.45
PBDT 326.46 456.67 -28.51 326.46 456.67 -28.51 1439.73 740.20 94.51
Depreciation 43.65 41.26 5.79 43.65 41.26 5.79 171.34 163.08 5.06
PBT 282.81 415.41 -31.92 282.81 415.41 -31.92 1268.39 577.12 119.78
TAX 72.29 103.34 -30.05 72.29 103.34 -30.05 309.98 134.80 129.96
Deferred Tax -1.31 -2.26 -42.04 -1.31 -2.26 -42.04 -11.52 20.11 -157.28
PAT 210.52 312.07 -32.54 210.52 312.07 -32.54 958.41 442.32 116.68
Equity 96.94 96.95 -0.01 96.94 96.95 -0.01 96.94 96.94 0.00
PBIDTM(%) 20.30 18.69 8.60 20.30 18.69 8.60 19.10 17.97 6.27

Gufic Biosciences Share Price

301.30 -1.35 (-0.45%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×